

Bri Biosciences Limited
騰盛博藥生物科技有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

Dear Shareholder,

April 28, 2023

Election of Means of Receipt and Language of Corporate Communications

Pursuant to Rules 2.07A and 2.07B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the articles of association of Brii Biosciences Limited (the “**Company**”), the Company is making available to you the following options for you to elect for the means of receipt and the languages of future corporate communications (the “**Corporate Communications**”) of the Company, which includes any document(s) to be issued by the Company for the information or action of any holders of its securities, including but not limited to: (a) directors’ reports, annual accounts together with the auditors’ reports and, where applicable, summary financial reports; (b) interim reports and, where applicable, summary interim reports; (c) notices of meetings; (d) listing documents; (e) circulars; (f) proxy forms; and (g) reply slips.

You may choose:

- (i) to read all future Corporate Communications published on the Company’s website (“**Website Version**”) instead of receiving printed copies; or
- (ii) to receive a printed English version of all future Corporate Communications only; or
- (iii) to receive a printed Chinese version of all future Corporate Communications only; or
- (iv) to receive both the printed English and Chinese versions of all future Corporate Communications.

To contribute to the protection of our environment, we encourage you to select the Website Version. Even if you have chosen the Website Version, you reserve the right at any time by giving reasonable notice in writing to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited (the “**Hong Kong Branch Share Registrar**”), to change your choice.

Please mark a “✓” in the appropriate box on the enclosed reply form (“**Reply Form**”) and sign and return it by post or by hand to the Hong Kong Branch Share Registrar at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong on or before May 26, 2023. If you post your Reply Form in Hong Kong, you may use the mailing label in the Reply Form and need not affix a stamp on the envelope when returning your Reply Form. Otherwise, please affix an appropriate stamp.

If the Company does not receive a duly completed and signed Reply Form from you (or another response from you indicating that you object to receiving the Website Version of Corporate Communications) on or before May 26, 2023, you will be deemed, until you inform the Company otherwise by reasonable notice in writing at the office of the Hong Kong Branch Share Registrar at the above address or by email to briibio-ecom@hk.tricorglobal.com, to have elected to receive all future Corporate Communications by Website Version instead of receiving them in printed form. In that event, when the Company makes a Corporate Communication, it will only send you a notification that the Corporate Communication has been made available on the Company’s website. The notification will be sent to you by email or by post at your address as it appears in the Company’s register of members maintained by the Hong Kong Branch Share Registrar.

You may at any time by reasonable notice in writing to the Hong Kong Branch Share Registrar at the above address or by email to briibio-ecom@hk.tricorglobal.com elect (i) to receive future Corporate Communications in printed form instead of by Website Version, or by Website Version instead of in printed form, or (ii) change the language in which you receive Corporate Communications in printed form. If you have elected (or are deemed to have elected) to receive Corporate Communications by Website Version and for any reason have difficulty in obtaining access to Corporate Communications on the Company’s website, the Company or the Hong Kong Branch Share Registrar will upon request send the relevant Corporate Communications to you in printed form and in the elected language version(s) free of charge.

Please note that English and Chinese versions of all future Corporate Communications will be available (a) in printed form from the Company or the Hong Kong Branch Share Registrar on request and (b) on the website of The Stock Exchange of Hong Kong Limited at <http://www.hkexnews.hk> and on the Company’s website at <http://www.briibio.com>.

Should you have any queries relating to this letter, please contact the Hong Kong Branch Share Registrar at (852) 2980 1333 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays).

Yours faithfully,
For and on behalf of
Brii Biosciences Limited
Dr. Zhi Hong
Chairman